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ABSTRACT 40 
 41 
Purpose: To investigate the effects of mild-to-moderate cystic fibrosis (CF) on the 42 
pulmonary oxygen uptake (V̇O2) kinetics of 7 pediatric patients (13.5 ± 2.8 y) versus 7 43 
healthy matched controls (CON; 13.6 ± 2.4 y). We hypothesized that CF would slow the V̇O2 44 
kinetic response at the onset of moderate (MOD) and very heavy (VH) intensity cycling. 45 
Methods: Changes in breath-by-breath V̇O2, near-infrared spectroscopy-derived muscle 46 
deoxygenation ([HHb]) at the m. vastus lateralis and thoracic bioelectrical impedance-47 
derived heart rate, stroke volume index (SVI) and cardiac index (CI) were measured during 48 
repeat transitions to MOD (90% of the gas exchange threshold) and VH (Δ60%) intensity 49 
cycling exercise. Results: During MOD, the phase II V̇O2 τ (p=0.84; effect size (ES) = 0.11) 50 
and overall mean response time (MRT) (p=0.52; ES=0.11) were not significantly slower in 51 
CF versus CON. However, during VH exercise, the phase II V̇O2 τ (p=0.02, ES=1.28) and 52 
MRT (p=0.01, ES=1.40) were significantly slower in CF. Cardiac function, central O2 53 
delivery (SVI and CI) and muscle [HHb] kinetics were unaltered in CF. However, the 54 
arterial-venous O2 content difference (C(a-v�)O2) was reduced during VH at 30 s (p=0.03, 55 
ES=0.37), with a trend for reduced levels at 0 s (p=0.07, ES=0.25), 60 s (p=0.05, ES=0.28) 56 
and 120 s (p=0.07, ES=0.25) in CF. Furthermore, ∆C(a-v�)O2 significantly correlated with the 57 
VH phase II V̇O2 τ (r= -0.85; p=0.02) and MRT (r = -0.79; p=0.03) in CF only. Conclusion: 58 
Impairments in muscle oxidative metabolism during constant work rate exercise are intensity-59 
dependent in young people with mild-to-moderate CF. Specifically, V̇O2 kinetics are slowed 60 
during VH but not MOD cycling and appear to be mechanistically linked to impaired muscle 61 
O2 extraction and utilization.  62 
 63 
Keywords: oxidative muscle metabolism; pulmonary disease; near-infrared spectroscopy; 64 
oxygen delivery; pediatrics.  65 
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INTRODUCTION 66 
 67 
Maximal O2 uptake (V̇O2max) is clinically important in patients with cystic fibrosis (CF), 68 
given associations with prognosis (26), risk of hospitalization (25) and health-related quality 69 
of life (11). V̇O2max by definition does not, however, represent the rate at which aerobic 70 
energy transfer adapts to the changing metabolic demands facing O2 transport and utilization 71 
during everyday life. In contrast, assessing the dynamic adjustment in pulmonary V̇O2 [time 72 
constant (τ) for the primary component (phase II)] at the onset of exercise provides a non-73 
invasive insight into muscle O2 consumption dynamics (21) and the breakdown of muscle 74 
phosphocreatine (PCr) (30, 4). Consequently, this parameter can provide insight into the 75 
factor(s) mediating muscle metabolic function and the integration of the respiratory, 76 
cardiovascular and muscular systems at the onset of exercise. Compared to healthy children 77 
(for a review see (2)), there is limited evidence in young people with CF for the V̇O2 kinetic 78 
response and its regulating mechanism(s)  79 
 80 
Slower V̇O2 kinetics have been reported in people with CF during incremental (34, 17), 81 
pseudo-random binary sequence (PRBS) (22) and constant work rate (CWR) exercise (19, 1). 82 
However, a similar V̇O2 kinetic response to healthy controls (11-15 y) has been documented 83 
during intense exercise (7). Methodological issues may explain these disparities. Firstly, 84 
during incremental and PRBS exercise the phase II portion of the V̇O2 response was not 85 
isolated, which is critical to reflect the kinetics of muscle O2 consumption (21). Secondly, the 86 
CWR exercise study by Hebestreit and colleagues (19) did not prescribe work rate within 87 
physiologically defined exercise intensity domains. Furthermore, semi-recumbent cycling 88 
was used which may negate muscle O2 delivery during exercise, and a mixed age group of 89 
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10-33 y, which would comprise a range of pulmonary function characteristics, were tested 90 
(19).  91 
 92 
According to the Fick principle, the rate of adjustment in V̇O2 is dictated by O2 delivery and 93 
utilization mechanisms but few studies have applied this to understand how CF modifies the 94 V̇O2 kinetic response to CWR exercise (42). Slower V̇O2 kinetics in CF have been linked to 95 
impaired O2 delivery (19), inferred from arterial O2 saturation (SpO2%). Although children 96 
with CF may present with early signs of cardiovascular abnormalities (18, 38, 29), impaired 97 
skeletal muscle oxidative capacity in CF is reported (30, 34, 40, 15, 12). The near-infrared 98 
spectroscopy (NIRS)-derived muscle deoxygenation (∆[HHb]) signal provides insight into 99 
the ratio of local muscle O2 delivery to muscle O2 utilization. Thus, changes in muscle HHb 100 
are considered to represent changes in muscle O2 extraction dynamics during exercise (e.g. 101 
16). Although it has been hypothesised that more rapid muscle HHb dynamics would be 102 
evident in the face of reduced central or muscle O2 delivery (16), children and adolescents 103 
with CF do not appear able to compensate in this manner during incremental exercise (30, 104 
34). This raises questions regarding the capacity of CF skeletal muscle to increase muscle O2 105 
extraction during exercise, but this has yet to be evaluated alongside V̇O2 kinetics during 106 
CWR cycling exercise.  107 
 108 
The aim of the study was to characterize the pulmonary V̇O2 kinetic response of children and 109 
adolescents with mild-to-moderate CF at the onset of moderate (MOD) and very heavy (VH) 110 
intensity cycling exercise. It was hypothesized that: 1) a longer phase II V̇O2 τ at the onset of 111 
MOD and VH exercise would be evident in CF; 2) slower cardiac output (?̇?) and more rapid 112 
[HHb] kinetics would be evident in CF during MOD and VH exercise; and 3) slower V̇O2 113 
kinetics would relate to reduced ?̇? and altered muscle ∆[HHb] dynamics in the CF group.  114 
5 
  
 115 
MATERIALS AND METHODS 116 
Study Participants. Seven young Caucasian individuals with stable, mild-to-moderate CF 117 
(Tables 1 and 2) and 7 controls (CON) (Table 2) participated. Inclusion criteria comprised a 118 
diagnosis of CF based on clinical features, an abnormal sweat test (sweat chloride > 60 119 
mmolL-1 / 100 mg sweat) and genotyping. Stable pulmonary function within 10% of best in 120 
the preceding 6 months and no symptomatic increase or weight loss within 2 weeks was also 121 
mandatory. Unstable non-pulmonary comorbidities and/or acute infection warranted 122 
exclusion. Ethics approval was granted by the South West NHS Research Ethics Committee. 123 
Informed written consent and assent was obtained from parent(s)/guardian(s) and 124 
participants.  125 
[Insert Tables 1 and 2 here] 126 
 127 
Experimental protocol 128 
Participants attended the laboratory five times over a two week period, at a similar time of 129 
day and separated by 24-48 h. Participants were advised to arrive rested and hydrated, > 2 h 130 
postprandial and having refrained from caffeine (> 2 h). All exercise was performed on a 131 
cycle ergometer (Lode, Groningen, The Netherlands or Lode Corival (Pediatric), Groningen).  132 
 133 
Visit 1: CPET protocol. Following anthropometric and pulmonary function measurements, a 134 
combined ramp incremental and supramaximal (Smax) CPET was used to determine V̇O2max 135 
and the gas exchange threshold (GET) (32, 33). This protocol involved an exhaustive ramp 136 
incremental (10-25 W·min-1) cycling test with a subsequent Smax (110% peak power output 137 
(PPO)) test to exhaustion, to confirm a valid V̇O2max measurement. Following a 3 min warm-138 
up (20 W), participants completed the incremental test to the point of volitional exhaustion, 139 
maintaining a cadence of 70-80 rpm throughout. Exhaustion was defined as a ≥10 rpm drop 140 
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in cadence for 5 consecutive seconds, despite strong verbal encouragement. Active (5 min 141 
cycling at 20 W) and then passive seated recovery (10 min) then preceded the Smax test. Smax 142 
verification consisted of a 3 min warm-up (20 W), followed by a ‘step’ transition to a CWR 143 
corresponding to 110% PPO. Upon volitional exhaustion (defined above), a 5 min active 144 
recovery (slow cycling at 20 W) concluded the combined CPET session.  145 
 146 
Visits 2-5: CWR exercise. For each visit the participants completed MOD and VH CWR 147 
exercise tests, comprising 6 min unloaded pedalling (10 W), followed by transitions to elicit 148 V̇O2 amplitudes corresponding to 90% GET and Δ60% (60% of the difference between the 149 
GET and V̇O2max) for 6 min. This equated to MOD work rates of 58 ± 24 W and 73 ± 35 W 150 
for CF and CON, respectively. During VH, CF and CON cycled at 121 ± 43 W and 150 ± 64 151 
W, respectively. Thirty minutes rest separated the MOD and VH transitions. Each set of 152 
MOD and VH transitions was performed on separate days, separated by ≥ 48 h and within a 2 153 
week period.  154 
 155 
Experimental measures 156 
Anthropometry and pulmonary function. Body mass (Seca 220; Vogel & Halke, 157 
Hamburg, Germany) and stature (Seca 220; Vogel & Halke, Hamburg, Germany) were 158 
measured to the nearest 0.01 kg and 0.01 m. Skinfold measurements (Harpenden; British 159 
Indicators, Burgess Hill, UK) were used to estimate percentage body fat (37). Forced vital 160 
capacity (FVC) and forced expiratory volume in 1 s (FEV1) were assessed using spirometry 161 
(Micromedical Microloop 3535, Numed, Sheffield, UK), and expressed as a percentage 162 
predicted using appropriate reference values (38).  163 
 164 
Gas exchange and pulse oximetry. Breath-by-breath changes in gas exchange and 165 
ventilation were determined using a metabolic cart (Metalyzer 3B Cortex, Biophysik, 166 
7 
  
Leipzig, Germany), which was calibrated each test using gases of known concentration and a 167 
3 L syringe (Hans Rudolph, Kansas City, MO). Fingertip SpO2% was measured on a beat-by-168 
beat basis at the fingertip using pulse oximetry (NONIN, Avant 4000, NONIN Medical Inc., 169 
USA). 170 
 171 
Near-infrared spectroscopy. A near-infrared spectrometer (Portamon, Artinis Medical 172 
Systems) was used to non-invasively measure [HHb] at the m. vastus lateralis. Details 173 
regarding this system have been outlined in our previous work in young people with CF 174 
during ramp incremental exercise (34). Briefly, this system consists of an emission probe, 175 
with three light sources emitting two wavelengths of light (760 and 850 nm) and a photon 176 
detector. Following cleaning and shaving of the area of interrogation, the wireless emitter-177 
detector unit was placed over the muscle belly, midway between the greater trochanter and 178 
lateral epicondyle of the femur. After marking of the placement area, the device was secured 179 
with tape (Kinesio® Tex) and a dark elastic bandage to minimize extraneous light interference 180 
with the near-infrared signal. The intensity of incident and transmitted light was recorded at 181 
continuously at 10 Hz.  182 
 183 
Thoracic Impedance. Beat-by-beat changes in heart rate (HR), SV and ?̇? were measured 184 
using a bioelectrical impedance cardiography system (PhysioFlow, PF-05, Manatec 185 
Biomedical, Paris, France) that has previously been used in CF (e.g. 2). This technique uses a 186 
high-frequency (75 kHz) and low-magnitude (1.8 mA) current across the thorax, to enable 187 
changes in thoracic impedance during the cardiac cycle to be recorded. Following preparation 188 
of the skin sites, electrodes were positioned on the forehead, base of the neck and above the 189 
supraclavicular fossa, and two positioned on the xiphoid process. Another set of two 190 
electrodes were used to determine a single electrocardiograph signal at the V1 and V6 191 
positions.  192 
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 193 
CPET parameters of aerobic function. The highest 15 s averaged V̇O2 from the ramp and 194 
Smax tests represented V̇O2max (32) and was normalized to fat-free mass (FFM) using the ratio 195 
standard method. The GET was identified using the V-slope method (5) and confirmed 196 
through visual inspection of the ventilatory equivalents for V̇O2 and V̇CO2.  197 
 198 
Pulmonary ?̇?O2 kinetics. Breath-by-breath changes in V̇O2 were analysed using 199 
methodology previously described by our laboratory (3, 8). Briefly, the four repeat transitions 200 
for both MOD and VH were linearly interpolated to 1 s, time aligned to exercise onset 201 
(i.e., t = 0 s) and ensemble averaged. The 1 s averaged V̇O2 response for the MOD and VH 202 
conditions for each participant were then baseline corrected, by subtracting the mean 203 V̇O2 between -60 and -5 s from the exercise response. The duration of phase I was visually 204 
assessed to account for the cardio-dynamic contribution to the V̇O2 kinetic response. The first 205 
21 ± 3 s and 17 ± 4 s of the MOD data and the first 19 ± 5 s and 16 ± 2 s for VH were omitted 206 
in CF and CON participants, respectively. The phase II portion of the V̇O2 response was then 207 
characterised using Equation 1 (GraphPad Prism; GraphPad Software, San Diego, CA): 208 
 209 V̇O2 (t) = Δ V̇O2 A  · (1 – e – (t –TD)/τ)                          Equation 1.  210 
 211 
 212 
where V̇O2 (t), Δ V̇O2 A, TD, and τ represent the value of V̇O2 at a given time (t), the amplitude 213 
change in V̇O2 from baseline to its asymptote, time delay, and the time constant of the 214 
response, respectively.  215 
 216 
The MRT was derived to describe the overall kinetics during both MOD and VH, by 217 
constraining the TD in Equation 1 to the onset of phase I and fitting to end-exercise. The 218 
functional V̇O2 gain of phase II was determined by dividing the phase II V̇O2 amplitude by the 219 
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change in work rate above baseline. End-exercise V̇O2 gain was calculated in a similar 220 
manner. For VH exercise, the V̇O2 slow-component onset and amplitude were determined in 221 
line with our previous work (3, 8). Briefly, Equation 1 was first fit up to the initial 60 s of 222 
exercise and then increased iteratively by 1 s to the end of the exercise bout (LabView, v 6.1, 223 
National Instruments, Newbury, UK). The best fit curve for the phase II portion of the 224 
response was established using: 1) a plot of the V̇O2 τ against time, to identify the point at 225 
which the influence of the V̇O2 slow component lengthened the estimated τ following an 226 
initial plateau; and 2) deviation from an optimal fitting of the model as judged by a 227 
systematic departure of the model’s residuals. The phase II parameter estimates from 228 
equation 1 were then resolved by least-squares non-linear regression (GraphPad Prism, 229 
GraphPad Software, San Diego, CA). The magnitude of the V̇O2 slow component was 230 
calculated as the difference between the mean of the final 30 s at 6 min of exercise and the 231 
phase II asymptote and was expressed in both absolute terms and relative to end-exercise 232 V̇O2. 233 
 234 
Muscle oxygenation kinetics. NIRS data were collected at 10 Hz, interpolated to 1 s 235 
intervals and expressed as a change, in arbitrary units (a.u.), from baseline. Subsequently, 236 
[HHb] profiles were 5 s averaged, time aligned to exercise onset and ensemble averaged to 237 
yield a single response. The dynamics of the primary and slow-component phases of the 238 
[HHb] response were modelled in a similar manner to V̇O2, with slight modification. The 239 
exponential-like increase in [HHb] after the onset of exercise occurred after a discernible 240 
delay. The time at which the exponential-like increase in [HHb] commenced was identified as 241 
the point of a 1 SD increase above baseline (3). Equation 1 was then applied to resolve the 242 
[HHb] TD and τ following removal of the data preceding the exponential-like increase. The 243 
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[HHb] MRT was calculated by summing TD and τ to provide an overall description of the 244 
kinetics in the primary phase.  245 
 246 
Heart rate, stroke volume, cardiac output and C(a-𝐯�)O2. Beat-by-beat changes in HR, SV 247 
and ?̇? were linearly interpolated to 1 s, time aligned and ensemble averaged to 30 s. The 248 
arterial-venous O2 content difference [C(a-v�)O2] was estimated via rearrangement of the Fick 249 
equation [C(a-v�)O2 = V̇O2/ ?̇?]. SV and ?̇? were normalized to FFM (12) using the ratio standard 250 
method, to determine the cardiac index (CI) and SV index (SVI). The ?̇?/V̇O2 ratio was used 251 
to provide an index of muscle O2 availability relative to metabolic rate.  252 
  253 
Statistical analyses 254 
Independent samples t-tests examined mean differences between CF and CON. Additionally, 255 
effect size [ES (d)] statistics determined the magnitude of the effect, using a pooled SD. The 256 
magnitude of the difference between variables of interest were explored using ES thresholds 257 
of trivial (< 0.2), small (> 0.2), moderate (> 0.5), large (> 0.8), and very large (> 1.0) (9). 258 
Changes in HR, SV, 𝑄 ̇ and C(a-v�)O2 were analysed using mixed model ANOVA. Significant 259 
interactions were followed up using independent samples t-tests. Pearson’s correlation 260 
coefficients assessed relationships between V̇O2 kinetics and mechanistic parameters of O2 261 
delivery and utilization. Statistical analyses were performed using SPSS (version 19.0, SPSS, 262 
Chicago, IL), with the null-hypothesis rejected at alpha level of 0.05.  263 
 264 
RESULTS 265 
Maximal cardiopulmonary exercise testing 266 
Descriptive characteristics and CPET data are presented in Table 2. There were no 267 
differences in body size and composition and lung function between CF and CON. V̇O2max 268 
was reduced in CF compared with CON when normalized using body mass but not FFM.   269 
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 270 
Pulmonary ?̇?O2 kinetics  271 
The V̇O2 responses during MOD and VH are presented in Figure 1 and the kinetic parameters 272 
in Table 3. There was no significant difference in baseline V̇O2 between the groups for either 273 
MOD or VH exercise (Table 3). For MOD, CF had no influence on either the phase II τ, TD 274 
or MRT. However, the phase II V̇O2 gain was lower in CF. During VH exercise, the V̇O2 275 
MRT and phase II τ were slower in CF. The phase II TD, amplitude and gain and end-276 
exercise V̇O2 were not altered in CF. A V̇O2 slow-component manifested in all VH responses, 277 
however the amplitude was similar between CF and CON.  278 
 279 
[Insert Table 3 here] 280 
  281 
Muscle oxygenation kinetics  282 
The group mean data for [HHb] and the corresponding kinetic parameters are shown in 283 
Figure 2 and Table S1 (Supplemental Digital Content 1 – muscle oxygenation kinetics of 284 
young CF patients and healthy control participants at the onset of moderate and very heavy 285 
intensity cycling exercise), respectively. The [HHb] response of one CF patient (male, 10 y, 286 
∆F508 homozygote) did not display exponential characteristics and was, in addition to their 287 
healthy control, excluded from [HHb] analyses. There was no difference between CF and 288 
CON for any of the [HHb] kinetic parameters during MOD or VH exercise. 289 
 290 
Heart rate, stroke volume index, cardiac index and C(a-𝐯�)O2. 291 
Group mean HR, CI, SVI and C(a-v�)O2 dynamics are presented in Figure 3. No significant 292 
time by disease state interaction effect for SVI was evident during either MOD (p = 0.09) or 293 
VH (p = 0.27). During VH there was a significant interaction between time and disease state 294 
for HR (p = < 0.01), with follow-up comparisons identifying a higher HR in CF at 30 s (p = 295 
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0.04, ES = 0.21). There was a significant main effect for disease state (p = 0.01) for CI to be 296 
lower in CF during MOD but not VH (p < 0.05). There was a time by disease state interaction 297 
(p = 0.03) for C(a-v)O2 during VH (Figure 3d), with extraction significantly reduced in CF at 298 
30 s (p = 0.02, ES = 0.37) and a trend towards reduced values at 0 s (p = 0.07, ES = 0.25), 60 299 
s (p = 0.05, ES = 0.28) and 120 s (p = 0.07, ES = 0.25). ?̇?/V̇O2 was not different between the 300 
groups for either intensity (p > 0.05).  301 
 302 
Relationships between ?̇?O2 kinetics and mechanistic parameters 303 
During MOD, the phase II V̇O2 τ significantly correlated with ∆[HHb] (r = 0.84; p = 0.04) in 304 
CF, whilst the MOD V̇O2 MRT correlated with ∆SVI in CON (r = -0.81; p = 0.03). During 305 
VH, the ∆C(a-v�)O2 significantly correlated with the phase II V̇O2 τ (r = -0.85; p = 0.02) and 306 
MRT (r = -0.79; p = 0.03) in CF. Furthermore, ∆?̇?/∆V̇O2 significantly correlated (r = 0.78; p 307 
= 0.04)  with the phase II V̇O2 τ in CF during VH exercise.     308 
 309 
DISCUSSION  310 
This is the first study to examine the dynamics of V̇O2 in children and adolescents with mild-311 
to-moderate CF at the onset of MOD and VH intensity cycling exercise, relative to 312 
adjustments in central O2 delivery and localized muscle (m. vastus lateralis) O2 extraction. 313 
The novel and original findings from this study are: 1) V̇O2 kinetics were slowed in CF during 314 
VH but not MOD; 2) no differences in muscle [HHb] kinetics were found between CF and 315 
CON during MOD and VH exercise; 3) during VH exercise only, C(a-v�)O2 was reduced in CF 316 
within the initial 60 s of exercise onset, and 4) the change in C(a-v�)O2 during VH exercise was 317 
significantly correlated with the phase II V̇O2 τ and MRT in CF. Collectively, these findings 318 
support the notion that impaired muscle oxidative metabolism in young CF patients is 319 
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dependent on the intensity of exercise and principally limited by muscular factors, which 320 
limit the extraction and utilisation of O2 during VH exercise  321 
 322 
Contrary to our hypothesis, neither the phase II or overall V̇O2 kinetics were slowed during 323 
MOD intensity cycling in young people with CF. This is consistent with early observations in 324 
similarly aged patients (11.1-15.3 y) with mild airway obstruction during 6 minutes cycling at 325 
1.7 W·kg-1 (7). In contrast, two studies have documented slower V̇O2 dynamics during 326 
exercise in patients with CF (22, 19), however methodological issues may explain this 327 
disparity. Kusenbach et al. (22) employed PRBS exercise which fails to isolate phase II of the 328 V̇O2 response. Although Hebestreit et al. (19) utilised CWR exercise and isolated phase II, 329 
work rate was not prescribed within physiologically defined intensity domains (18). This 330 
process meant patients were likely to be exercising across the MOD-severe intensity domains 331 
which, if the intensity was above the GET, would be consistent with our present findings of 332 
slowed V̇O2 kinetics during VH exercise. Hebestreit and colleagues also used semi-supine 333 
exercise (19), which may reduce muscle perfusion and slow V̇O2 dynamics (20). Finally, the 334 
combination of adult and paediatric patients (10-33 y) could have contributed to slow V̇O2 335 
kinetics, since slower phase II kinetics were recently documented in adults with more 336 
advanced CF (22 ± 4 y) during submaximal cycling (1). 337 
 338 
An interesting finding in this study was that the influence of CF on oxidative muscle 339 
metabolism appears to be intensity dependent. This is based on the finding that the phase II 340 V̇O2 τ and MRT were slowed only during VH exercise and the ES was very large (> 1.0). 341 
This is of clinical importance, since slower V̇O2 kinetic response will incur a greater O2 342 
deficit and a greater degree of substrate-level phosphorylation (increased lactic acid and PCr 343 
breakdown) and the accumulation of fatigue-inducing metabolites (e.g., inorganic phosphate 344 
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and hydrogen ions), which may impair exercise tolerance especially during VH exercise in 345 
young people with CF. An exercise intensity dependence to the impaired oxidative 346 
metabolism in CF corresponds with earlier observations in adolescent patients during a 90 s 347 
high-intensity exercise challenge performed within a 31Phosphorous Magnetic Resonance 348 
Spectroscopy scanner environment, but not shorter duration or less intense exercise (39). This 349 
may reflect the greater physiological challenge to mitochondrial aerobic metabolism elicited 350 
by higher intensities. 351 
 352 
The longer phase II V̇O2 τ of patients with CF (10-33 y; FEV1: 37-98% predicted) has 353 
previously been linked to inadequate O2 delivery, inferred by a significant relationship with 354 
SpO2 (19). In the current study, bulk blood flow, as inferred using the CI (?̇?), was not 355 
profoundly altered during either MOD or VH exercise in CF. Furthermore, V̇O2 kinetics were 356 
not mechanistically linked to the CI and SVI dynamics in this group of patients, despite 357 
previous reports that early signs of cardiac dysfunction may present in paediatric patients 358 
with CF (18, 34). Although CFTR is involved in the regulation of cardiomyocyte contraction 359 
(36) and gene mutation targeted therapies have been shown to increase SV in adolescents 360 
with CF (35), the current findings indicate that central O2 delivery does not principally limit 361 V̇O2 kinetics in young CF patients. This is further supported by research demonstrating that 362 
elevating SpO2 through the inspiration of hyperoxic gas does not improve the kinetics of V̇O2 363 
in patients with CF (22). However, it must be acknowledged that only central indices of O2 364 
delivery, which are relatively poor indicators of O2 delivery at the local muscle level during 365 
exercise (24), were obtained in these studies.  366 
 367 
However, considering the findings in the present study, the impaired V̇O2 kinetics during VH 368 
exercise were related to the capacity of skeletal muscle to extract and utilize O2. For the first 369 
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time, this study investigated the [HHb] dynamics of young patients with CF during CWR 370 
exercise, with similar kinetics observed between the groups. If muscle O2 availability was 371 
limiting oxidative metabolism in CF, a compensatory acceleration in the rate of O2 extraction 372 
would be expected (16). This was not observed in the present study and this finding 373 
corresponds with earlier studies during incremental exercise using both NIRS (34) and 374 
respiratory mass spectroscopy (30). Whilst this finding shows that the rate of O2 extraction 375 
taking place was not different in CF compared to CON, [HHb] does not reflect the amount of 376 
O2 extraction taking place. This can be physiologically interpreted from the C(a-v�)O2 377 
parameter.  378 
 379 
Interestingly, we observed a significant reduction in C(a-v�)O2 in CF during the early stages of 380 
VH exercise (see Figure 3D), which corresponds with the timing of the phase II portion of the 381 V̇O2 response, although the corresponding effect sizes were small. Furthermore, ∆C(a-v�)O2 382 
significantly correlated with the phase II V̇O2 τ and MRT during VH in CF only. These 383 
findings suggest that the amount of muscle O2 extraction and utilization is impaired in this 384 
patient group near the onset of exercise and is mechanistically linked to the dynamics of V̇O2. 385 
These findings support previous speculations regarding a peripheral limitation slowing V̇O2 386 
kinetics in patients with CF (19). This O2 extraction and utilization impairment may be 387 
explained by structural and functional changes in skeletal muscle that are evident in CF (40, 388 
12, 23). Although a recent study has provided conflicting data (41), slower post-exercise PCr 389 
recovery kinetics, measured using 31Phosporous magnetic resonance spectroscopy, suggest 390 
impaired muscle oxidative capacity in both the  m. vastus lateralis and forearm muscle (40, 391 
12). More recently, reduced local muscle oxidative capacity was inferred from the recovery 392 
of m. vastus lateralis O2 consumption following 15 s of electrical stimulation and subsequent 393 
repeated transient arterial occlusions (15). Evidence of CF-specific muscle metabolic 394 
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abnormalities (lower adenosine triphosphate concentration ([ATP]) and ATP:PCr at rest and 395 
significantly higher end-exercise pH values) (40) also support the present suggestions 396 
regarding a muscular abnormality in this patient group.   397 
 398 
The cause(s) of an intramuscular impairment in CF are currently unknown, although several 399 
factors have been proposed. Reduced antioxidant capacity, arising from systemic 400 
inflammation and/or oxidative damage, may lower mitochondrial efficiency (39). However, it 401 
may also be a consequence of the CFTR genetic mutation. CFTR is expressed in skeletal 402 
muscle cells (23) and in vitro study of leucocyte mitochondria in patients with CF 403 
demonstrates that properties of complex I of the respiratory chain are significantly altered 404 
(10). Furthermore, absence of CFTR from skeletal muscle has been shown to dysregulate 405 
calcium homeostasis, augment inflammatory or atrophic gene expression signatures and 406 
increase diaphragm weakness (14). Conversely, improving CFTR (dys)function using 407 
Ivacaftor shows potential to improve aerobic exercise function in adolescents with CF (35). 408 
Recent evidence that vascular endothelial (dys)function is associated with a poorer V̇O2max in 409 
young people with CF (28, 29) has been reported. However, the impact of impaired vascular 410 
function on the ability of people with CF to deliver O2 locally for extraction also requires 411 
further investigation.   412 
 413 
Whilst the present study provides the first robust investigation of the V̇O2 kinetic response in 414 
young CF patients, there are a number of limitations to be considered. NIRS exercise 415 
measurements in this population have recently been outlined in greater detail elsewhere (34), 416 
however include a restricted, heterogenous and superficial area of interrogation and possible 417 
inter-site variation in [HHb]. To minimize these limitations, the NIRS device was secured to 418 
the same anatomical region of all participants to eradicate inter-individual regional 419 
17 
  
differences within the m. vastus lateralis and [HHb] responses were standardized to the total 420 
[HHb] amplitude to provide a physiologic normalisation (6). Furthermore, adipose tissue 421 
thickness at the site of interrogation was not measured, which precludes comparing amplitude 422 
changes between the groups. Although the utilized thoracic impedance device has been 423 
validated in CF patients (27), this technique provides a non-invasive estimate of SV 424 
and   more detailed echocardiography indices of ventricular function, in addition to further 425 
measurements of vascular endothelial function would be insightful. Further, since CFTR is 426 
expressed in human vasculature and vascular endothelial dysfunction has been related to 427 V̇O2max in young CF patients (28, 29), contribution to altered V̇O2 kinetics warrants further 428 
investigation. Finally, since muscle fibre type composition and recruitment were not 429 
measured herein, discrepancies in fibre type composition and recruitment strategies between 430 
the groups cannot be excluded.  431 
 432 
These findings help us to further understand how young people with CF respond to the 433 
increased metabolic demand during activities of daily living and fatiguing exercise. Whilst 434 
children and adolescent with mild-to-moderate CF appear to respond in a similar manner to 435 
their healthy counterparts during MOD exercise, the slowed V̇O2 kinetics at the onset of 436 
exercise above the GET may well be linked to reduced exercise tolerance, which should be 437 
considered by the exercise practitioner when considering exercise prescription strategies for 438 
this patient group. Promisingly, identifying the rate limiting determinant(s) of pulmonary V̇O2 439 
kinetics in individuals with CF may provide viable targets for intervention.  440 
 441 
To conclude, this study demonstrates that the V̇O2 kinetics of paediatric patients with CF are 442 
slowed during VH but not MOD intensity cycling exercise. Impaired skeletal muscle 443 
oxidative metabolism in this patient group is intensity dependent and appears to be 444 
18 
  
mechanistically linked to an intrinsic intramuscular impairment which limits O2 extraction 445 
and utilization. Identifying the rate limiting determinant(s) of pulmonary V̇O2 kinetics in 446 
individuals with CF may provide viable targets for intervention in the future.  447 
 448 
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Supplemental Digital Content 1.doc  Muscle oxygenation kinetics of young CF patients and 584 
healthy control participants at the onset of moderate and very heavy intensity cycling 585 
exercise.   586 
 587 
 588 
Figure Legends 589 
 590 
Figure 1. Mean V̇O2 profile for cystic fibrosis (○ white circles) versus healthy (● black 591 
circles) children and adolescents during moderate (A, C) and very heavy (B, D) intensity 592 
cycling exercise. Figures C and D provide the normalized to end-exercise so that the 593 
differences in the phase II region of the V̇O2 response can be observed. The vertical dotted 594 
line illustrates the onset of exercise from a 10 W baseline. Data are presented as 5-s averages 595 
 596 
 597 
Figure 2. Mean [HHb] profile for cystic fibrosis (○ white circles) and healthy (● black 598 
circles) young people during moderate (A,C) and very heavy (B,D) intensity cycling exercise. 599 
Figures C and D provide the normalized to end-exercise so that the differences in the phase II 600 
region of the [HHb] response can be observed The vertical dotted line denotes the onset of 601 
exercise from a 10 W baseline. Data are presented as 5-s averages. 602 
 603 
 604 
Figure 3. Group mean heart rate (A), fat-free mass (FFM) normalized stroke volume (B), 605 
FFM normalized cardiac output (C) and FFM normalized arterial-venous O2 content 606 
difference [C(a-v)O2] (D) dynamics of young cystic fibrosis patients (○ white circles) and 607 
healthy age- and gender-matched controls (● black circles) during moderate (1) and very 608 
heavy (2) intensity cycling exercise. The vertical dotted line denotes the onset of exercise 609 
from a 10 W baseline. Data are mean and SD and 30-s averages. * denotes P < 0.05, i.e. 610 
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significant mean difference between CF patients and healthy controls, whilst + denotes a 611 
statistical trend (p = 0.07).  612 
 613 
TABLES 
 
Table 1. Baseline clinical characteristics for the young CF patients upon initiation into the 
study.  
 
Variable Value (mean ± SD) Range 
CFTR genotype: 
Homozygote ∆F508  
∆F508/ 2184delA 
∆F508/ G55ID 
 
4 
1 
1 
 
 
 
 
∆F508/ P67L 1  
   
Chronic P. Aeruginosa infection a “chronic,” n = 1; 
“intermittent,” n = 2 
“free,” n = 3 
“never,” n = 1 
Shwachman score 85 ± 5 80-90 
Northern score b 4 ± 1 3-6 
Pancreatic insufficient n = 7  
CF-related diabetes n = 1  
CF-related liver disease 
IVABs (days in last year) 
n = 1 
11 ± 9 
 
0-24 
 
Values are means ± SD, with the range also displayed where suitable, unless otherwise stated. 
CFTR, cystic fibrosis transmembrane conductance regulator; P. Aeruginosa; Pseudomonas Aeruginosa; 
Shwachman score - scoring 4 separate aspects of the disease profile; general activity; physical examination; 
nutritional status; and chest radiographic findings, using the most recent clinical review information. A total of 
100 points represents a perfect score of health; IVABs, intravenous antibiotics; aAccording to Leeds Criteria, 
“chronic”, > 50% of the preceding 12 months were P. aeruginosa culture positive; “intermittent”, ≤50% of the 
preceding 12 months were P. aeruginosa culture positive; “never”, no growth of P. aeruginosa for the previous 
12 months, having previously been P. aeruginosa culture positive; “free”, P. aeruginosa has never been 
cultured.   
b Provides evidence of radiographic chest findings. Maximum score is 20, with 20 being the most severe.  
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Table 2. Baseline anthropometric, pulmonary function and maximal cardiopulmonary 
exercise testing data for young patients and healthy age- and gender-matched control 
participants upon initiation into the study.  
 
 
Values are means ± SD unless otherwise stated. M, males; F, females; BMI, body mass index; FVC, forced vital 
capacity; FEV1, forced expiratory volume in 1 s; CPET, cardiopulmonary exercise testing; V̇O2max, maximal 
oxygen uptake; FFM, fat-free mass; GET, gas exchange threshold; MRT, mean response time; PPO, peak power 
output; TTE, time to exhaustion; Smax, supramaximal verification phase; SpO2%, arterial oxygen saturation.  
aAccording to Stanojevic et al. (2009). 
 
  
Variable CF 
Mean ± SD 
CON 
Mean ± SD 
p-value ES (d) 
Gender 5 M, 2 F 5 M, 2 F - - 
Age (y) 13.5 ± 2.80 13.6 ± 2.40 0.93 -0.04 
Stature (m)  1.61 ± 0.20 1.62 ± 0.17 0.92 -0.05 
Body mass (kg) 60.7 ± 22.8 52.4 ± 17.8 0.46 0.38 
BMI (kg·m2) 22.6 ± 4.5 19.4 ± 2.9 0.14 0.79 
FFM (kg) 49.5 ± 19.9 40.1 ± 12.5 0.30 0.54 
FVC (L) 3.91 ± 1.29 4.08 ± 1.50 0.82 -0.12 
FVC ( % predicteda) 106 ± 10 107 ± 17 0.82 -0.11 
FEV1 (L) 3.27 ± 1.00 3.59 ± 1.26 0.61 -0.26 
FEV1 (% predicteda) 102 ± 6 110 ± 12 0.17 -0.72 
 
CPET parameters 
- - - - V̇O2max (L·min-1) 2.08 ± 0.74 2.51 ± 0.91 0.34 -0.49 V̇O2max  (mL·kg-1·min-1) 34.30 ± 8.88 47.75 ± 3.56 < 0.01* -1.79 V̇O2max/FFM (mL·kg-1·min-1) 51.87 ± 34.90 65.52 ± 24.65 0.42 -0.42 V̇O2 at the GET (L·min-1) 1.09 ± 0.31 1.38 ± 0.48 0.20 -0.67 
GET% (% of V̇O2max ) 53.7 ± 6.4 55.2 ± 3.3 0.57 -0.28 
Ramp PPO (W) 162 ± 61 208 ± 86 0.27 -0.58 
Ramp TTE (s) 546 ± 111 729 ± 113   0.01* -1.52 
SpO2% (%) 95 ± 3 98 ± 1   0.04* -1.23 
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Table 3. Pulmonary oxygen uptake kinetics in CF and CON during MOD and VH exercise.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Variable CF 
Mean ± SD 
CON 
Mean ± SD 
 
p-value ES (d) 
Moderate intensity exercise 
 
Baseline V̇O2 (L·min-1) 0.62 ± 0.13 0.68 ± 0.16 0.47 -0.38 
Phase II V̇O2  τ (s) 25.2 ± 6.7 26.1 ± 8.4 0.84 -0.11 
Phase II V̇O2  TD (s) 21.7 ± 7.3 14.8 ± 7.1 0.10  0.90 
Phase II V̇O2 amplitude (L·min-1) 0.42 ± 0.20 0.64 ± 0.34 0.16 -0.76 
Phase II V̇O2 gain (mL·min-1·W-1) 8.6 ± 1.3 10.4 ± 1.4   0.03* -1.21 V̇O2 mean response time (s) 44.6 ± 8.0 41.6 ± 8.9 0.52 0.33 
 
Very heavy intensity exercise 
 
Baseline V̇O2 (L·min-1) 0.68 ± 0.15 0.76 ± 0.19 0.37 -0.46 
Phase II V̇O2  τ (s) 37.5 ± 10.8 25.1 ± 6.5   0.02* 1.28 
Phase II V̇O2 TD (s) 14.7 ± 6.1 14.6 ± 3.0 0.96 0.03 
Phase II V̇O2  amplitude (L·min-1) 0.97 ± 0.34 1.26 ± 0.54 0.25 -0.60 
Phase II  V̇O2 gain (mL·min-1·W-1) 8.9 ± 0.8 9.2 ± 1.2 0.51 -0.34 V̇O2 slow-component onset (s) 144 ± 29 117 ± 21 0.07 0.99 V̇O2 slow-component amplitude (L·min-1)   0.19 ± 0.15 0.16 ± 0.13 0.74 0.17 V̇O2 slow-component relative amplitude (%) 9.0 ± 6.3 6.7 ± 3.8 0.43 0.40 
End-exercise V̇O2 (L·min-1) 1.83 ± 0.59 2.18 ± 0.83 0.38 -0.46 
End-exercise V̇O2  gain (mL·min-1·W-1) 9.9 ± 1.3 10.3 ± 0.9 0.56 -0.30 V̇O2 mean response time (s) 74.6 ± 19.4 51.6 ± 8.3   0.01* 1.40 
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Table S1. Muscle oxygenation kinetics of young CF patients and healthy control participants at the onset of moderate and very heavy intensity 
cycling exercise.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Four participants per group, two healthy controls presented with a monoexponential response and their matched patients were subsequently also removed from the slow-
component analyses; b three per group, two healthy controls presented with a monoexponential response and one CF patient had an abnormal negative response following the 
slow-component onset, therefore their matched patients were subsequently also removed from the slow-component analyses; c one CF patient presented with a 
monoexponential response and her healthy match was subsequently also removed from the slow-component analyses.    
Variable CF (Mean ± SD) CON (Mean) ± SD p-value ES (d) 
 
Moderate intensity exercise 
 
Baseline [HHb] (a.u.) -0.01 ± 0.08 0.01 ± 0.03 0.74 -0.17 
Phase II [HHb] τ (s) 12.5 ± 8.8 9.0 ± 5.0 0.42 0.44 
Phase II [HHb] TD (s) 14.8 ± 3.3 11.9 ± 5.6 0.30 0.57 
[HHb] mean response time (s) 27.3 ± 7.6 20.9 ± 2.2 0.08 0.99 
Phase II [HHb] amplitude (a.u.) 1.63 ± 1.73 2.76 ± 1.75 0.29 -0.60 
[HHb] slow-component onset (s) a 104 ± 19 103 ± 30 0.95 0.04 
[HHb] slow-component amplitude (a.u.) b 0.30 ± 0.58 0.51 ± 0.50 0.43 -0.33 
[HHb] slow-component relative amplitude (%) b 11.37 ± 6.90 18.10 ± 5.27 0.25 -0.86 
End-exercise [HHb] (a.u.) 1.99 ± 2.12 3.12 ± 1.91 0.35 -0.52 
Very heavy intensity exercise 
 
Baseline [HHb] (a.u.) 0.00 ± 0.03 0.02 ± 0.03 0.60 0.29 
Phase II [HHb] τ (s) 13.0 ± 12.4 9.4 ± 3.9 0.51 0.34 
Phase II [HHb] TD (s) 11.3 ± 2.7 9.9 ± 2.7 0.41 0.46 
[HHb] mean response time (s) 24.2 ± 11.9 19.3 ± 1.8 0.34 0.49 
Phase II [HHb] amplitude (a.u.) 4.11 ± 4.70 6.20 ± 3.07 0.39 -0.48 
[HHb] slow-component onset (s) c  151.0 ± 73.4 96.0 ± 29.03 0.18 0.84 
[HHb] slow-component amplitude (a.u.) c 1.15 ± 0.65 1.69 ± 0.48 0.17 -0.85 
[HHb] slow-component relative amplitude (%) c 26.5 ± 13.6 21.6 ± 6.2 0.49 0.40 
End-exercise [HHb] (a.u.) 5.13 ± 5.12 7.81 ± 3.43 0.31 -0.56 



